GLUC IR Post re 10-K
"Quotes" from Glucose Health, Inc.'s Fiscal 2016 10-K Annual Report with Audited Financial Statements and "Comments" from CEO/CFO Murray Fleming:
1) "We generated revenues of $313,229 and $4,272 for the years ended December 31, 2016 and 2015, respectively."
"Not many micro-caps have a market capitalization 50% less than annual revenues in most recent fiscal year."
2) "For the period ending December 31, 2016, we generated a gross profit before operating expenses, a loss from operations and a net loss per share."
"Rarely do micro-caps generate gross profits."
3) "the Company executed a non-recourse receivables financing agreement with Citibank..."
"Very rarely do micro-caps qualify for money-center bank financing."
4) "For the year ended December 31, 2016, we had total operating expenses of $105,814, as compared to total operating expenses of $156,570 for the year ended December 31, 2015. The decrease of $50,756 or 32%, in our operating expenses between the two periods is due to continued further reductions in general and administrative expenses and stock based compensation."
"Very rarely can micro-caps grow revenue significantly and reduce administrative expenses and stock-based compensation, at the same time."
5) For the year ended December 31, 2016, we had a net loss of $410,443 or $0.15 per share with $323,796 of this net loss for the period related to the recording of interest expense and amortization of debt discount, a non-cash adjustment to reconcile net loss to net cash used in operations."
"In other words, in fiscal 2016, GLUC was only $86,647 short of achieving positive EBITDA."
